ストックスクリーナーアプリを入手
1.55
4.76%
0.08
前日終値:
$1.47
開ける：
$1.48
24時間の取引高:
262.67K
Relative Volume:
0.86
時価総額：
$48.04M
収益：
$1.05M
当期純損益:
$-48.82M
株価収益率:
-0.847
EPS:
-1.83
ネットキャッシュフロー:
$-47.49M
1週間 パフォーマンス:
-4.94%
1か月 パフォーマンス:
+1.32%
6か月 パフォーマンス:
+41.28%
1年 パフォーマンス:
-22.61%
1日の値動き範囲:
$1.42
$1.61
1週間の範囲:
$1.39
$1.648
52週間の値動き範囲:
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
名前
Actinium Pharmaceuticals Inc
セクター
電話
646-767-3870
住所
275 Madison Avenue, 7th Floor, New York, NY
ATNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.54 | 48.04M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.14 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.75 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.84 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
641.85 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.67 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-02-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 開始されました | B. Riley Securities | Buy |
| 2020-11-05 | 開始されました | Alliance Global Partners | Buy |
| 2017-12-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 再開されました | ROTH Capital | Buy |
| 2017-09-14 | 開始されました | Maxim Group | Buy |
| 2016-08-25 | 開始されました | ROTH Capital | Buy |
| 2016-02-29 | 開始されました | H.C. Wainwright | Buy |
| 2015-10-15 | 開始されました | FBR Capital | Outperform |
| 2014-10-01 | 開始されました | MLV & Co | Buy |
| 2014-07-22 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Actinium Pharmaceuticals Inc (ATNM) 最新ニュース
Analyzing drawdowns of Actinium Pharmaceuticals Inc. with statistical toolsPredictive Analytics for Equity Growth Potential - Newser
Can Actinium Pharmaceuticals Inc. hit a new high this monthFree Market Surge Signal for Swing Traders - Newser
Visualizing Actinium Pharmaceuticals Inc. stock with heatmapsFree Stock Selection With High Accuracy - Newser
Can technical indicators confirm Actinium Pharmaceuticals Inc.’s reversalFree Short Term Trading Opportunity Watch - Newser
Has Actinium Pharmaceuticals Inc. formed a bullish divergenceNeural Model for Stock Price Movement - Newser
Why Actinium Pharmaceuticals Inc. stock attracts strong analyst attentionFree Oversold Recovery Opportunity Stocks - Newser
What’s the recovery path for long term holders of Actinium Pharmaceuticals Inc.Free AI Driven Buy Alert Trade Blueprint - Newser
Actinium Pharmaceuticals Inc. stock daily chart insightsFree Earnings Play Trade Plan With Alerts - Newser
Visual analytics tools that track Actinium Pharmaceuticals Inc. performanceAsset Safety Selection Using Quantitative Analysis - Newser
Actinium Pharmaceuticals Inc.’s volatility index tracking explainedWeekly Trend Screener with Momentum Picks - Newser
Analyzing Actinium Pharmaceuticals Inc. with risk reward ratio chartsDividend Strategy Summary With 10-Year Outlook - Newser
Published on: 2025-08-09 00:23:20 - Newser
Actinium: Q2 Earnings Snapshot - San Francisco Chronicle
Is Actinium Pharmaceuticals Inc. a Top Dividend Stock to Watch in 2025Immediate Entry Point Prediction Strategy - Newser
Financial Contrast: Gemini Therapeutics (NASDAQ:GMTX) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
What institutional flow reveals about Actinium Pharmaceuticals Inc.Investment Position Summary with Timeframe Forecast - Newser
Can machine learning forecast Actinium Pharmaceuticals Inc. recoveryShort Term Profit Strategy with Entry Cues - Newser
What moving averages say about Actinium Pharmaceuticals Inc.AI Intraday Market Movement Prediction Tool - Newser
Is it time to cut losses on Actinium Pharmaceuticals Inc.Volatility Analysis and Entry Risk Mapping - Newser
How strong is Actinium Pharmaceuticals Inc. company’s balance sheetFree Buy/Sell Signal Notifications - Jammu Links News
What are the latest earnings results for Actinium Pharmaceuticals Inc.Consistent triple-digit returns - Jammu Links News
What analysts say about Actinium Pharmaceuticals Inc. stockSuperior returns - Jammu Links News
What is the dividend policy of Actinium Pharmaceuticals Inc. stockHigh-performance stocks for savvy investors - Jammu Links News
Is it the right time to buy Actinium Pharmaceuticals Inc. stockAccelerated capital growth - Jammu Links News
What institutional investors are buying Actinium Pharmaceuticals Inc. stockAchieve breakthrough gains with expert advice - Jammu Links News
How does Actinium Pharmaceuticals Inc. compare to its industry peersGet daily expert analysis on top stocks - Jammu Links News
When is Actinium Pharmaceuticals Inc. stock expected to show significant growthAchieve consistent double-digit returns - Jammu Links News
What is Actinium Pharmaceuticals Inc. company’s growth strategyExceptional growth trajectory - jammulinksnews.com
What are analysts’ price targets for Actinium Pharmaceuticals Inc. in the next 12 monthsInvest confidently with market-leading analysis - Jammu Links News
Is Actinium Pharmaceuticals Inc. a growth stock or a value stockUnprecedented market success - Jammu Links News
What makes Actinium Pharmaceuticals Inc. stock price move sharplyDaily Technical Forecast for Quick Gains - Newser
Key External Factors That Drive Actinium Pharmaceuticals Inc. Stock Price MovementsReal Time Growth Signal with Smart Setup - Newser
Actinium Pharmaceuticals shares rise 5.73% intraday after presenting positive data for ATNM-400 in prostate cancer treatment. - AInvest
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficac - PR Newswire
Will Actinium Pharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsFree Risk Managed Intraday Trade Alerts - Newser
Actinium Pharmaceuticals’ ATNM-400 Shows Promise in Prostate Cancer Treatment, Earning Buy Rating - TipRanks
Actinium Pharmaceuticals Inc. recovery potential after sell offWatchlist Generator for Smart Money Signals - Newser
Published on: 2025-07-31 05:11:29 - metal.it
What’s next for Actinium Pharmaceuticals Inc. stock priceTrade Scanner With Buy Zone Alerts Flagged - metal.it
How Actinium Pharmaceuticals Inc. stock performs during market volatilityShort Term Alpha Signals Insight - beatles.ru
How to interpret RSI for Actinium Pharmaceuticals Inc. stockChart Based Entry Tool for ROI Traders - Newser
Actinium Pharmaceuticals Inc.’s Price Action Aligns with Quant SignalsTriple Digit Return Stock Predictions Released - beatles.ru
Can Actinium Pharmaceuticals Inc. Rally Enough to Break EvenTriple Return Setup With Risk Control Explained - metal.it
Published on: 2025-07-29 14:09:30 - metal.it
Is Actinium Pharmaceuticals Inc. showing signs of accumulationMarket Downturn Defense Strategy Analysis - Newser
Is Actinium Pharmaceuticals Inc. stock a growth or value playFree Smart Trend Trading with Weekly Signals - Newser
Does Actinium Pharmaceuticals Inc. fit your quant trading modelDaily Market Momentum and Pressure Analysis - Newser
Actinium Pharmaceuticals Inc (ATNM) 財務データ
収益
当期純利益
現金流量
EPS
0.83%
3.03%
大文字化:
|
ボリューム (24 時間):